Treatment Approaches for EGFR-Mutated Lung Cancers
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 September 2026 | Viewed by 54
Special Issue Editor
Special Issue Information
Dear Colleagues,
Targeting EGFR (epidermal growth factor receptor)-mutated lung cancer represents a major paradigm shift in the management of non-small-cell lung cancer (NSCLC), transitioning from conventional cytotoxic chemotherapy to precision-based targeted therapy. This transformation has significantly improved clinical outcomes and ushered in a new therapeutic era.
The role of EGFR tyrosine kinase inhibitors (TKIs) has expanded from metastatic and unresectable disease to resected early-stage NSCLC in the adjuvant setting, marking an important milestone in precision oncology. To further enhance efficacy and overcome resistance, combination strategies have been explored. EGFR–MET bispecific antibodies and anti-angiogenic therapies have demonstrated promising clinical benefit, particularly in resistant settings.
In patients with brain metastases, the combination of Osimertinib and chemotherapy has shown significant improvements in response rates, progression-free survival (PFS) and overall survival (OS).
Although immunotherapy has historically demonstrated limited efficacy in EGFR-mutated NSCLC, recent studies suggest that combining immunotherapy with chemotherapy and/or anti-angiogenic agents may improve outcomes after progression on prior EGFR TKI therapy.
Resistance to EGFR TKIs remains inevitable and involves multiple mechanisms, including EGFR-dependent alterations (T790M, C797S and amplification), EGFR-independent pathways (MET and HER2/3 amplification, downstream signaling and AXL activation) and phenotypic transformation such as small-cell lung cancer and epithelial–mesenchymal transition. Molecular reassessment through re-biopsy or liquid biopsy is essential to guide subsequent treatment.
Circulating tumor DNA (ctDNA) is an emerging tool for detecting minimal residual disease, guiding therapy and predicting survival.
This Special Issue highlights current and emerging strategies to improve outcomes in EGFR-mutated lung cancer.
Dr. Busyamas Chewaskulyong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NSCLC
- EGFR TKIs
- osimertinib
- chemotherapy
- EGFR–MET bispecific antibodies
- immunotherapy
- anti-angiogenesis
- resistance mechanisms
- ctDNA
- brain metastases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
